MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keaf173

Медицинская библиотека · Rheumatology (Oxford, England) · 2025

Evaluating the therapeutic potential of tofacitinib in Sjögren's disease: a comprehensive clinical and immunological assessment.

Liu Qinghong, Zeng Yuqing, Xing Xiaoyan, Huang Bo, Feng Ruiling, Wang Yifan, Wang Naidi, Zhang Xia, Li Yuhui, Su Linchong, Jacob Alexander, Ambrus Julian L, Shen Long, Suresh Lakshmanan, Yu Di, Lin Xiang, He Jing

Клиническое исследование II фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

To evaluate the efficacy, safety and immunological effects of tofacitinib in patients with Sjögren's disease (SjD), focusing on its impact on disease activity and immune cell modulation.

METHODS

Two independent cohort studies, one retrospective (Cohort I) and one prospective (Cohort II), were conducted to investigate the efficacy of oral tofacitinib treatment in patients diagnosed with SjD. All participants were evaluated for changes in disease activity and lab parameters. Circulating T cells were analysed, focusing on follicular helper T (Tfh) cells and peripheral helper T (Tph) cells.

RESULTS

In cohort I, 112 patients treated with tofacitinib showed a significant improvement in the ESSDAI score [median (IQR), 8.00 (4.25, 15.75) vs 6.50 (2.25, 12.75), P < 0.001]. In cohort II, ten patients completed the 12-month treatment period. There was a significant reduction in ESSDAI scores at the sixth month compared with baseline (P = 0.001). In total, 80% (8/10) of patients achieved a decrease of at least one point or 15% in ESSPRI scores. A significant reduction in the proportion of Th17 cells was observed (mean ± SD, 14.84 ± 7.70 vs 7.74 ± 4.24, P = 0.008). A decrease in Tfh and Tph cells was also observed, along with decreased pSTAT-3 levels in CD4+ T cells and disease activity scores. No serious adverse events were observed in the two cohorts.

CONCLUSIONS

Tofacitinib effectively improves disease activity and immune regulation in SjD, and it is associated with suppressing Tfh and Tph cells, suggesting its potential as a treatment option.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05087589.

Для цитирования: Liu Qinghong, Zeng Yuqing, Xing Xiaoyan, Huang Bo, Feng Ruiling, Wang Yifan, Wang Naidi, Zhang Xia, Li Yuhui, Su Linchong, Jacob Alexander, Ambrus Julian L, Shen Long, Suresh Lakshmanan, Yu Di, Lin Xiang, He Jing. Evaluating the therapeutic potential of tofacitinib in Sjögren's disease: a comprehensive clinical and immunological assessment.. Rheumatology (Oxford, England). 2025. DOI: 10.1093/rheumatology/keaf173.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.